Switching from infliximab to biosimilar in inflammatory bowel disease
Biological therapy has revolutionized the treatment of inflammatory bowel disease (IBD). After the expiration of patents for biological innovator products, development of biosimilars increased. CT-P13 was the first biosimilar approved for the same indications as the reference product; however, the a...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2019
|
| Sorozat: | THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
12 |
| doi: | 10.1177/1756284819842748 |
| mtmt: | 30658417 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/16408 |
| LEADER | 02235nab a2200229 i 4500 | ||
|---|---|---|---|
| 001 | publ16408 | ||
| 005 | 20200116123345.0 | ||
| 008 | 190821s2019 hu o 0|| zxx d | ||
| 022 | |a 1756-283X | ||
| 024 | 7 | |a 10.1177/1756284819842748 |2 doi | |
| 024 | 7 | |a 30658417 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a zxx | ||
| 100 | 1 | |a Milassin Ágnes | |
| 245 | 1 | 0 | |a Switching from infliximab to biosimilar in inflammatory bowel disease |h [elektronikus dokumentum] / |c Milassin Ágnes |
| 260 | |c 2019 | ||
| 300 | |a Azonosító: 1756284819842748-Terjedelem: 11 p | ||
| 490 | 0 | |a THERAPEUTIC ADVANCES IN GASTROENTEROLOGY |v 12 | |
| 520 | 3 | |a Biological therapy has revolutionized the treatment of inflammatory bowel disease (IBD). After the expiration of patents for biological innovator products, development of biosimilars increased. CT-P13 was the first biosimilar approved for the same indications as the reference product; however, the approval was based on extrapolated data from rheumatoid arthritis and ankylosing spondylitis. Our aim was to review clinical studies about switching from originator infliximab (IFX-O) to biosimilar infliximab (IXF-B) in IBD, focusing on recently published data and the future of biosimilars.The PubMed database was searched for original articles published up to 1 December 2018 reporting data on IFX-B in IBD.A total of 29 studies assessing switching from IFX-O to IFX-B, 14 assessing induction therapy with IFX-B were found. Efficacy, safety and immunogenicity were discussed. Studies confirm that CT-P13 is safe and equally efficient as the reference product for both induction and maintenance therapy; and that switching from the reference product to biosimilar is non-inferior to continuous biosimilar use. However, efficacy and safety data on Flixabi (SB2) in IBD patients is lacking.Switching from the originator to a biosimilar in patients with IBD is acceptable, although scientific and clinical evidence is lacking regarding reverse switching, multiple switching and cross-switching among biosimilars in IBD patients. | |
| 700 | 0 | 1 | |a Fábián Anna |e aut |
| 700 | 0 | 1 | |a Molnár Tamás |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/16408/1/30658417_Milassin_2019.pdf |z Dokumentum-elérés |